fore Hepatitis C late diagnosis cases, an aftermath of the COVID-19 pandemic in Barcelona, Spain.

> Juan Carlos Ruiz Cobo, Adriana Palom, Mar Riveiro-Barciela, Rafael Esteban, María Buti



October 11-13, 2022 | Barceló Sevilla Renacimiento



Ayuntamiento de Sevilla





# **Background and aims**



In May 2016, the World Health Assembly endorsed the *Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021*. The GHSS calls for the elimination of viral hepatitis as a public health threat by 2030 (reducing new infections by 90% and mortality by 65%).



**Background and aims** 



GLOBAL HEALTH

# From Jan. 2020: China Identifies New d Virus Causing Pneumonialike Illness

The new coronavirus doesn't appear to be readily spread by humans, but researchers caution that more study is needed.

and mortality by 65%).



### **Background and aims**

# Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21

Lancet 2022; 399: 1513–36




Figure 4: Global distribution of the ratio between estimated excess mortality rate due to the COVID-19 pandemic and reported COVID-19 mortality rate, for the cumulative period 2020-21

Findings Although reported COVID-19 deaths between Jan 1, 2020, and Dec 31, 2021, totalled 5.94 million worldwide, we estimate that 18.2 million (95% uncertainty interval 17.1–19.6) people died worldwide because of the COVID-19 pandemic (as measured by excess mortality) over that period. The global all-age rate of excess mortality due to the



Background and aims: epidemiological context before covid19 pandemic

Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

HCV	2018-2019
Patients	1785
Male (%)	63.9
Age, mean (years)	55.9
Spanish-born (%)	87.3
Late presentation (%)	27
<ul> <li>Late stage disease (%)</li> <li>HCC(%)</li> <li>Descompensated cirrhosis</li> </ul>	<b>5.2</b> 2,6 2,6



**Background and aims** 


• To evaluate if the pandemic limited the access to first time specialist care for HCV patients.

• To evaluate if the pandemic increased the amount of HCV patients with late presentation.



# **Patients and methods**

# Vall d'Hebron Hospital (Barcelona)



Retrospective-Prospective study performed between 2018 and 2021.

#### Study cohort

- Attending 1<sup>st</sup> hepatology consultation.
- Chronic HCV infection (HCV RNA +).
- Patientes > 18 years-old.
- Exclusion of acute hepatitis.
- Patients were referred by a primary care physician or other specialists.
- Demographic and clinical characteristics were separated into three periods:
  - preCOVID (2018-19).
  - COVD Lockdown (2020).
  - COVID (2021).
- Liver fibrosis was assessed by noninvasive methods (transient elastography or FIB-4).



# **Patients and methods**


# Late presentantion

Presentation with advanced liver disease in untreated patients with chronic hepatitis B and C	A patient with chronic hepatitis B or C and significant fibrosis assessed by one of the following: serologic fibrosis score ≥ F3 (assessed by APRI score > 1.5, FIB-4 > 3.25, Fibrotest > 0.59 or alternatively a transient elastography (FibroScan) > 9.5 kPa) or liver biopsy (≥ METAVIR stage F3) in patients with no previous antiviral treatment <sup>a</sup> .
Presentation with late stage liver disease in untreated patients with chronic hepatitis B and C	Presence of at least one symptom of decompensated cirrhosis (jaundice, hepatic encephalopathy, clinically detectable ascites, variceal bleeding) and/or hepatocellular carcinoma in patients with no previous antiviral treatment <sup>b</sup> .




### **Results: patients attended**

A total of 376 patients with Hepatitis C were visited during this period: 229 before and 147 during COVID19 pandemic, **representing a decrease by 36% of patients attended.** 



# **Results**


In our cohort 77% of patients were born in Spain and 23% outside Spain predominantly from Eastern Europe, Pakistan and South America



Spain (n = 290) Georgia (n = 29) Pakistan (n = 14) Russia (n = 6) Ukraine (n = 5) Brazil (n = 3) Venezuela (n = 3) Romania (n = 3)




# **Results: late presentation**




**42,5%** of patients attended in 2021 had late presentation and therefore significant fibrosis at the time of first specialist consultation therefore they would require long term follow up.


# **Results: late stage liver disease**



## **Results: late stage liver disease**



## **Results: late stage liver disease**



Conclusion

# • The COVID19 pandemic caused a reduction of outpatient attendance at first hepatology consultation by 36%.

• The limited access to screening and diagnosis could have **increased the percentage of patients with late presentation for care in 2021**.

• This could lead to a delay in WHO elimination plans for HCV.

